These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A. Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366 [Abstract] [Full Text] [Related]
3. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). Vernaleken I, Fellows C, Janouschek H, Bröcheler A, Veselinovic T, Landvogt C, Boy C, Buchholz HG, Spreckelmeyer K, Bartenstein P, Cumming P, Hiemke C, Rösch F, Schäfer W, Wong DF, Gründer G. J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428 [Abstract] [Full Text] [Related]
4. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. Vernaleken I, Janouschek H, Raptis M, Hellmann S, Veselinovic T, Bröcheler A, Boy C, Cumming P, Hiemke C, Rösch F, Schäfer WM, Gründer G. Int J Neuropsychopharmacol; 2010 Aug; 13(7):951-60. PubMed ID: 20392299 [Abstract] [Full Text] [Related]
5. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Gründer G, Landvogt C, Vernaleken I, Buchholz HG, Ondracek J, Siessmeier T, Härtter S, Schreckenberger M, Stoeter P, Hiemke C, Rösch F, Wong DF, Bartenstein P. Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387 [Abstract] [Full Text] [Related]
8. [18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics. Rominger A, Cumming P, Xiong G, Koller G, Böning G, Wulff M, Zwergal A, Förster S, Reilhac A, Munk O, Soyka M, Wängler B, Bartenstein P, la Fougère C, Pogarell O. Addict Biol; 2012 Mar; 17(2):490-503. PubMed ID: 22023291 [Abstract] [Full Text] [Related]
9. [18F]fallypride characterization of striatal and extrastriatal D2/3 receptors in Parkinson's disease. Stark AJ, Smith CT, Petersen KJ, Trujillo P, van Wouwe NC, Donahue MJ, Kessler RM, Deutch AY, Zald DH, Claassen DO. Neuroimage Clin; 2018 Mar; 18():433-442. PubMed ID: 29541577 [Abstract] [Full Text] [Related]
10. Reduced D2/D3 Receptor Binding of Extrastriatal and Striatal Regions in Temporal Lobe Epilepsy. Bernedo Paredes VE, Buchholz HG, Gartenschläger M, Breimhorst M, Schreckenberger M, Werhahn KJ. PLoS One; 2015 Mar; 10(11):e0141098. PubMed ID: 26544593 [Abstract] [Full Text] [Related]
11. Striatal and extrastriatal dopamine release in the common marmoset brain measured by positron emission tomography and [(18)F]fallypride. Ota M, Ogawa S, Kato K, Masuda C, Kunugi H. Neurosci Res; 2015 Dec; 101():1-5. PubMed ID: 26232153 [Abstract] [Full Text] [Related]
12. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'h C, Mazière B, Paillère-Martinot ML. J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918 [Abstract] [Full Text] [Related]
13. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Gründer G, Fellows C, Janouschek H, Veselinovic T, Boy C, Bröcheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rösch F, Schaefer WM, Vernaleken I. Am J Psychiatry; 2008 Aug; 165(8):988-95. PubMed ID: 18381901 [Abstract] [Full Text] [Related]
14. Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Mukherjee J, Yang ZY, Brown T, Lew R, Wernick M, Ouyang X, Yasillo N, Chen CT, Mintzer R, Cooper M. Nucl Med Biol; 1999 Jul; 26(5):519-27. PubMed ID: 10473190 [Abstract] [Full Text] [Related]
15. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S. Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809 [Abstract] [Full Text] [Related]
16. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY. Neuropsychopharmacology; 2005 Dec; 30(12):2283-9. PubMed ID: 16123775 [Abstract] [Full Text] [Related]
17. Alteration of dopamine D2/D3 receptor binding in patients with juvenile myoclonic epilepsy. Landvogt C, Buchholz HG, Bernedo V, Schreckenberger M, Werhahn KJ. Epilepsia; 2010 Sep; 51(9):1699-706. PubMed ID: 20384765 [Abstract] [Full Text] [Related]
18. High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol. Vandehey NT, Moirano JM, Converse AK, Holden JE, Mukherjee J, Murali D, Nickles RJ, Davidson RJ, Schneider ML, Christian BT. J Cereb Blood Flow Metab; 2010 May; 30(5):994-1007. PubMed ID: 20040928 [Abstract] [Full Text] [Related]
19. Altered connectivity between striatal and extrastriatal regions in patients with schizophrenia on maintenance antipsychotics: an [18 F]fallypride PET and functional MRI study. Kim JH, Cumming P, Son YD, Kim HK, Joo YH, Kim JH. Synapse; 2018 Dec; 72(12):e22064. PubMed ID: 30063263 [Abstract] [Full Text] [Related]